Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
845 studies found for:    "Ovarian epithelial cancer"
Show Display Options
Rank Status Study
1 Completed Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Conditions: Primary Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer
Intervention: Biological: recombinant interleukin-12
2 Withdrawn Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian Carcinoma Patients at High Risk of Progression
Condition: Ovarian Carcinoma
Intervention: Drug: Fondaparinux
3 Active, not recruiting Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma
Conditions: Ovarian Neoplasms;   Ovarian Epithelial Cancer
Interventions: Biological: DCVAC/OvCa with Standard of Care;   Biological: DCVAC/OvCa sequentially chemotherapy;   Drug: Standard of Care
4 Unknown  Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer (EOC): A Phase III Randomized Study
Condition: Ovarian Carcinoma
Intervention: Other: timing of surgery
5 Withdrawn Whole Abdomen Radiation in Conjunction With Intraperitoneal Chemotherapy for the Treatment of Small Volume Recurrent Ovarian Carcinoma Limited to the Peritoneal Cavity
Condition: Recurrent Ovarian Carcinoma
Interventions: Drug: Cisplatin;   Radiation: Whole Abdomen Radiotherapy
6 Not yet recruiting p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
Conditions: Ovarian Epithelial Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
Interventions: Drug: p53 gene;   Drug: Cisplatin;   Drug: Paclitaxel
7 Unknown  Study on Neutropenia Induced by Adjuvant Paclitaxel/Carboplatin Chemotherapy in Patients With Epithelial Ovarian Cancer
Condition: Epithelial Ovarian Cancer
Intervention:
8 Active, not recruiting Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE)
Condition: Ovarian Carcinoma
Interventions: Device: NovoTTF-100L(O);   Drug: Paclitaxel
9 Terminated
Has Results
A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy
Condition: Epithelial Ovarian Cancer
Interventions: Drug: CAELYX;   Drug: Topotecan HCl
10 Completed Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian Cancer
Conditions: Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: sorafenib tosylate;   Other: laboratory biomarker analysis
11 Recruiting Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma
Condition: Ovarian Carcinoma
Intervention:
12 Completed FES-PET to Determine ER-expression in Epithelial Ovarian Cancer
Condition: Epithelial Ovarian Cancer
Intervention: Other: FES-PET
13 Terminated Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy
Condition: Ovarian Carcinoma
Intervention: Drug: Cytophosphan, Celecoxib, Methotrexate
14 Completed Green Tea Intake for the Maintenance of Complete Remission in Women With Advanced Ovarian Carcinoma
Condition: Ovarian Carcinoma
Intervention: Dietary Supplement: Double-Brewed Green Tea
15 Active, not recruiting Live After an Epithelial Ovarian Cancer: Multidisciplinary Assessment of Effects and Long-term Remission in Patients Needs.
Condition: Epithelial Ovarian Cancer
Intervention: Other: Gynecological consultation
16 Recruiting REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression
Condition: Ovarian Carcinoma
Interventions: Drug: Tamoxifen;   Drug: Regorafenib
17 Unknown  Safety of Active Immunotherapy in Subjects With Ovarian Cancer
Condition: Ovarian Epithelial Cancer
Intervention: Biological: Procure
18 Completed Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-type
Condition: Epithelial Ovarian Cancer
Interventions: Drug: Pegylated liposomal doxorubicin;   Drug: Panitumumab
19 Terminated Intraperitoneal (IP) Cisplatin Given With Paclitaxel to Treat Epithelial Ovarian Cancer
Condition: Epithelial Ovarian Cancer
Intervention: Drug: Intraperitoneal (IP) Cisplatin
20 Completed Treatment of Paclitaxel Plus Carboplatin Followed by Gemcitabine Plus Carboplatin for Patients With Epithelial Ovarian Cancer
Condition: Epithelial Ovarian Cancer
Interventions: Drug: gemcitabine;   Drug: carboplatin;   Drug: paclitaxel

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.